Category Coronavirus

A TRIPS-COVID Waiver and Overlapping Commitments to Protect Intellectual Property Rights Under International IP and Investment Agreements

[Henning Grosse Ruse-Khan and Federica Paddeu] This paper considers legal implications that are likely to emerge from the implementation of a TRIPS Waiver decision. Assuming that a Waiver is adopted in the form presented in the May 2021 proposal by South Africa and India et al, we review the interaction between the Waiver and other commitments to protect IP rights under international IP and investment treaties. Our principal research question is to analyze whether domestic measures implementing the Waiver are compatible with the implementing State’s other obligations to protect IP rights established under multilateral IP treaties, IP and Investment Chapters of FTAs as well as BITs.

Utilising Public Health Flexibilities in the Era of COVID-19: An Analysis of Intellectual Property Regulation in The OAPI and MENA Regions of Africa

[Yousuf A. Vawda and Bonginkosi Shozi] Abstract: The paper explores the unique approaches to IP protection in the countries belonging to the Organisation Africaine de la Propriété Intellectuelle/African Intellectual Property Organization (OAPI) and the Middle East and North Africa (MENA) regions; the limited extent to which legal and policy frameworks with regard to TRIPS flexibilities have been adopted and implemented in pursuit of access to medicines in those countries; and makes recommendations in order to optimise the use of the flexibilities in advancing public health objectives. In the context of the COVID-19 pandemic, the impact of IP rights on access, and some approaches to countering the challenges to access are also discussed.

The proposal for waiver of WTO’s TRIPS Agreement to prevent, contain and treat COVID-19: investigating the benefits and challenges for low- and middle-income countries

[Sanath Wijesinghe, Chaminya Adikari, and Ruwanthika Ariyaratna] Abstract: This article examines the benefits of the TRIPS waiver for low- and middle-income countries with particular reference to the challenges that these countries may face in the manufacturing and purchasing stages of COVID-19 vaccines. We assess arguments for and against the TRIPS waiver and suggest actionable solutions that could be provided by global policy actors to enable low- and middle-income countries to overcome such challenges.

Vaccines, Medicines and COVID-19: How Can WHO Be Given a Stronger Voice?

[Germán Velásquez] The considerable health, economic and social challenge that the world faced in early 2020 with COVID-19 continued and worsened in many parts of the world in the second half of 2020 and into 2021. How can an agency like WHO be given a stronger voice to exercise authority and leadership? This book is a collection of research papers produced by the author between 2020 and early 2021 that helps answer this question. The topics address the state of thinking and debate – particularly with regard to medicines and vaccines – that would enable a response to this pandemic or subsequent crises that may emerge.

Potential Claims related to IP and Public Health in Investment Agreements: COVID-19, the Proposed TRIPS Waiver and Beyond

[Cynthia Ho] An under-examined issue during the COVID-19 crisis is the potential liability of countries under investment agreements for taking steps to mitigate COVID issues.  This Policy Brief provides an overview of how countries may be liable to companies for taking domestic action to protect public health, including pre-COVID claims related to Intellectual Property (IP), as well as possible claims because of COVID emergency measures, including claims that could result if the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) Waiver was adopted.  The current COVID-19 crisis opens the opportunity to consider and reevaluate the unnecessary threat of international agreements that allow for investment claims and potentially consider their termination.

Copyright in the Time of COVID-19: An Australian Perspective

[Amanda Bellenger and Helen Balfour] Abstract: COVID-19 has raised many challenges in terms of applying Australian copyright legislation and related policies to higher education context. This paper describes the experience of Copyright Officers at Curtin University and Murdoch University from the initial stages of border-control measures affecting delivery of learning materials to students in China, to the wider disruption of the pandemic with many countries implementing lockdown measures, to the current environment where remote delivery is the “new normal.”

Waive Intelletual Property rights and Save Lives

[Srividhya Ragavan] In October of 2020, when India and South Africa proposed a waiver from certain provisions of the TRIPS agreement, it was meant to increase local manufacturing capacity in these countries... The waiver has an additional role to play in the larger trade schema. In enabling vaccination of populations across the globe, the waiver would be critical to normalize global trade.

Vaccine Knowledge Needs to Be a global Public good

[Ellen 't Hoen] The global health crisis caused by the COVID-19 outbreak has laid bare the lack of an effective mechanism for the sharing of IP and technology required to produce the diagnostics, therapeutics and vaccines to respond to the pandemic. The WHO established, in May 2020, well before the first vaccines came to market, the COVID-19 Technology Access Pool (C-TAP): a mechanism to allow the sharing of the IP, knowhow, data and technology that are needed to meet the global need for 11 billion doses of COVID-19 vaccines, as well as diagnostics and treatments. Companies have so far refused to collaborate with C-TAP, citing the age-old talking point that sharing IP is detrimental to future investments in pharmaceutical innovations – even though the development of COVID-19 vaccines has been de-risked with unprecedented amounts of public financing.

Access to COVID-19 Vaccines in High-, Middle-, and Low-Income Countries Hosting Clinical Trials

[Reshma Ramachandran, Joseph S. Ross, and Jennifer E. Miller] The COVID-19 pandemic has led to the rapid development of multiple vaccines, tested in clinical trials located in several countries. Low- and middle-income countries have experienced significant delays in vaccine access despite initiatives aiming to ensure fair distribution, such as COVID-19 Vaccines Global Access (COVAX). Because pharmaceuticals do not receive consistent and timely authorization for use in lower-income countries where they are tested, we examined authorization and delivery of COVID-19 vaccines recommended by the World Health Organization (WHO) in the countries where they were tested.

Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries

[MPP Press Release] Pfizer and the Medicines Patent Pool (MPP), a United Nations-backed public health organization working to increase access to life-saving medicines for low- and middle-income countries, today announced the signing of a voluntary license agreement for Pfizer’s COVID-19 oral antiviral treatment candidate PF-07321332, which is administered in combination with low dose ritonavir (PF-07321332; ritonavir). The agreement will enable MPP to facilitate additional production and distribution of the investigational antiviral, pending regulatory authorization or approval, by granting sub-licenses to qualified generic medicine manufacturers, with the goal of facilitating greater access to the global population.

A Critical Appraisal of the COVID-19 TRIPS Waiver

[Peter Yu] This chapter offers a critical appraisal of the COVID-19 TRIPS waiver proposal. It begins by identifying the arguments for the waiver. It then turns to arguments against the proposal, including those made by policymakers and commentators who question the waiver's effectiveness. After documenting both sides of the debate, this chapter concludes by exploring whether we should support the text-based negotiations on this instrument – and if so, whether we should also support its adoption.

Non-Patent Intellectual Property Barriers to COVID-19 Vaccines, Treatment and Containment

[Sean Flynn, Erica Nkrumah and Luca Schirru] Abstract: As the World Trade Organization considers a proposal to waive or otherwise address intellectual property barriers to the global response to the COVID-19 pandemic, most of the attention given by scholars and policy makers has been focused on patents. The original proposals by South Africa and India, as well as the groundbreaking support of the United States, however, explicitly applied to all forms of intellectual property. This paper documents many instances where non-patent forms of intellectual property create barriers to the global scale up of access to vaccines, treatments, and the ability to contain the virus through social distancing. Addressing the full scope of such barriers would assist the global efforts to combat COVID-19.